Metrics as of 10/16/2026, 08:46 PM (Berlin time), refresh in progress.
Immunovant Stock
Immunovant, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Eric Venker
- Employees
- 315
- Market cap
- $5.5 B
- IPO
- 21/06/2019
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase operating within the biotechnology industry. Headquartered in Durham with additional operations in New York, New York, the company functions as a subsidiary under the umbrella of Roivant Sciences Ltd. The company employs 315 employees and…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Immunovant stock: price history
1D
-3.0%
1W
-12.4%
1M
-26.6%
6M
-8.9%
YTD
+5.0%
1Y
+53.3%
2Y
-8.5%
5Y
+206.0%
10Y
–
Next earnings date
Next earnings date
09/11/2026 (in 23 days)
Volatility around earnings
~60% stronger price swings than usual
Immunovant stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Average business model without a clear megatrend link or with mixed signals.
Immunovant is a biopharmaceutical company in clinical development stage that specializes in developing novel monoclonal antibodies for treating autoimmune diseases. The focus is on the active pharmaceutical ingredient Batoclimab, which blocks the neonatal FcRn receptor. The company is currently conducting clinical trials in phases IIa and II for various indications such as myasthenia gravis and thyroid eye disease. Immunovant is a subsidiary of Roivant Sciences Ltd. Since the company has not yet brought any products to market, current revenue data from product sales are not available.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Moderate
- Moat
- Narrow
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Immunovant
Analyst assessment of Immunovant
PRICE TARGET LOW
US$40.00
CONSENSUS
US$40.00
MEDIAN
US$40.00
PRICE TARGET HIGH
US$40.00
0
STRONG BUY
18
BUY
4
HOLD
1
SELL
0
STRONG SELL
23
TOTAL · Buy
As of: 04/08/2026
Immunovant stock metrics
P/E
-9.46
P/B
7.46
EV/EBITDA
-8.76
RETURN ON EQUITY
-20.8%
NET MARGIN
-2,159.6%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
41.1%
FLOAT SHARES
84,824,088
AVG. DAILY VOLUME (30D)
1,523,410
Insider transactions (SEC)
Stout Jay S
Van Tuyl Christopher
Gloria Melanie
Stout Jay S
Venker Eric
Institutional holders
Comparable stocks
Frequently asked questions about Immunovant stock
What does Immunovant do?
Immunovant, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Eric Venker, the company employs around 315 people.
The IPO was on 21/06/2019; the stock trades on NASDAQ under the ticker IMVT.
What do analysts say about Immunovant stock?
23 analysts rate the stock, the consensus is Buy (as of 04/08/2026).
The average price target is US$40.00, ranging from US$40.00 to US$40.00, with a median of US$40.00.
This is an external assessment, not a statement by Market Jury.
When does Immunovant report next?
The next earnings date is 09/11/2026.
Around past earnings, price swings were roughly 60% stronger than usual.
Does Immunovant pay a dividend?
No, Immunovant currently does not pay a dividend.
Which stocks are comparable to Immunovant?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Immunovant stock analyzed?
Clicking "Analyze stock" lets five strategies assess Immunovant against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.